Eli Lilly, Novo Nordisk and Sanofi produce over 90% of the global insulin supply and the PBMs CVS Caremark, Express Scripts and OptumRx administer pharmacy benefits for around 80% of prescription claims managed.
The lawsuit, filed in the California Superior Court in Los Angeles, argues that because competition is highly limited in both their markets, these six companies are able to keep ‘aggressively hiking’ the list price of insulin at the expense of patients, violating the state’s Unfair Competition Law…
